Toll Like Receptor 4 (hToll or CD284 or TLR4) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) – Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)

The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Batu Biologics Inc

BioLineRx Ltd

Biomedica Management Corp

eTheRNA Immunotherapies NV

Formune SL

GlaxoSmithKline Plc

Harbor Therapeutics Inc

Immune Design Corp

Immunovo BV

Kyorin Pharmaceutical Co Ltd

NovImmune SA

Reliance Life Sciences Pvt Ltd

TaiwanJ Pharmaceuticals Co Ltd

Vascular Biogenics Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Toll Like Receptor 4 (hToll or CD284 or TLR4) Overview 10

Therapeutics Development 11

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Stage of Development 11

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Therapy Area 12

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Indication 13

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Products Glance 16

Late Stage Products 16

Early Stage Products 17

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Companies 18

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Universities/Institutes 23

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment 25

Assessment by Monotherapy/Combination Products 25

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development 32

Batu Biologics Inc 32

BioLineRx Ltd 33

Biomedica Management Corp 34

eTheRNA Immunotherapies NV 35

Formune SL 36

GlaxoSmithKline Plc 37

Harbor Therapeutics Inc 38

Immune Design Corp 39

Immunovo BV 40

Kyorin Pharmaceutical Co Ltd 41

NovImmune SA 42

Reliance Life Sciences Pvt Ltd 43

TaiwanJ Pharmaceuticals Co Ltd 44

Vascular Biogenics Ltd 45

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles 46

ApTLR-4FT - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

BL-1110 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

C-34 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CRX-526 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

DMT-210 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

EDA-HPVE7 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

EDA-NS3 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

EDA-TRP2 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

EDAGP-120 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

G-100 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Glyco-23 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

GSK-1795091 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

HE-3286 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

hp-91 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

ibudilast - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

ISAS-01 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

JKB-117 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

JKB-119 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

JKB-121 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

naltrexone hydrochloride - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

NI-0101 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

P-13 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

P-16 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

P-7 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

P-MAPA - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

PEPA-10 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

RSCL-0520 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

RSCL-0521 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecules to Antagonize TLR2 and TLR4 for Immunology and Inflammation - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

TWJ-201 - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

VB-201 - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

VB-703 - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Projects 97

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products 102

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Featured News & Press Releases 103

Dec 09, 2016: MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland 103

Dec 05, 2016: Immune Design Provides Update on Discovery Platform G100 For Intratumoral Immunotherapy 104

Nov 17, 2016: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study 104

Nov 10, 2016: MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis 105

Oct 30, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland 105

Oct 11, 2016: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis 106

Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients 106

Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS 107

Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 108

Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate G100 At ASCO 108

May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 109

May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 110

Apr 21, 2016: Immune Design Announces Presentations on G-100 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 110

Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada 111

Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016 112

Appendix 114

Methodology 114

Coverage 114

Secondary Research 114

Primary Research 114

Expert Panel Validation 114

Contact Us 114

Disclaimer 115

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Development by Companies, H2 2016 (Contd..2) 21

Products under Development by Companies, H2 2016 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H2 2016 23

Products under Investigation by Universities/Institutes, H2 2016 24

Assessment by Monotherapy/Combination Products, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Pipeline by Batu Biologics Inc, H2 2016 32

Pipeline by BioLineRx Ltd, H2 2016 33

Pipeline by Biomedica Management Corp, H2 2016 34

Pipeline by eTheRNA Immunotherapies NV, H2 2016 35

Pipeline by Formune SL, H2 2016 36

Pipeline by GlaxoSmithKline Plc, H2 2016 37

Pipeline by Harbor Therapeutics Inc, H2 2016 38

Pipeline by Immune Design Corp, H2 2016 39

Pipeline by Immunovo BV, H2 2016 40

Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 41

Pipeline by NovImmune SA, H2 2016 42

Pipeline by Reliance Life Sciences Pvt Ltd, H2 2016 43

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2016 44

Pipeline by Vascular Biogenics Ltd, H2 2016 45

Dormant Projects, H2 2016 97

Dormant Projects (Contd..1), H2 2016 98

Dormant Projects (Contd..2), H2 2016 99

Dormant Projects (Contd..3), H2 2016 100

Dormant Projects (Contd..4), H2 2016 101

Discontinued Products, H2 2016 102

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 25

Number of Products by Mechanism of Actions, H2 2016 26

Number of Products by Stage and Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports